859210-68-7

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 859210-59-6 1-(3'-amino-5'-O-benzyl-2'-O-tert-butyldimethylsilyl-3'-C-cyano-3'-deoxy-3'-N-mesyl-β-D-ribofuranosyl)-3-N-tert-butoxycarbonylthymine 
• 859210-57-4 1-(3'-amino-5'-O-benzyl-2'-O-tert-butyldimethylsilyl-3'-C-cyano-3'-deoxy-3'-N-mesyl-β-D-ribofuranosyl)thymine 
• 668486-90-6 1-(3'-amino-5'-O-benzyl-3'-C-cyano-3'-deoxy-3'-N-mesyl-β-D-ribofuranosyl)thymine 
• 65-71-4 thymin 
• 859210-67-6 1-(3'-amino-5'-O-benzyl-2'-O-tert-butyldimethylsilyl-3'-C-cyano-3'-deoxy-3'-N-mesyl-3'-N-methyl-β-D-ribofuranosyl)-3-N-tert-butoxycarbonylthymine 

Relevant academic research and scientific papers

First synthesis and evaluation of the inhibitory effects of Aza analogues of TSAO on HIV-1 replication

Aza TSAO-T derivatives bearing a dihydroisothiazole dioxide ring instead of an oxathiole dioxide ring at the C-3′ position on the sugar moiety were prepared. We have synthesized four families of compounds depending on substitution at both N-3 and N-2″. Bi

Synthesis of AZA analogues of TSAO

TSAO derivatives which were first synthesized in 1992 have shown strong inhibitory effect and selectivity against HIV-1 (Camarasa, M.J.; Perez-Perez, M.J.; San-Felix, A.; Balzarini, J.; De Clercq, E. J. Med. Chem. 1992, 35, 2721-2727). The structure-activ